Last reviewed · How we verify
antihypertensive therapy
antihypertensive therapy is a Small molecule drug developed by Center of Personalized Medicine, Pirogova. It is currently in Phase 2 development.
Antihypertensive therapy is used to treat hypertension and prevent its complications, such as stroke, heart failure, kidney failure, and myocardial infarction. Reducing blood pressure by 5 mmHg can decrease the risk of stroke by 34% and ischemic heart disease by 21%.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | antihypertensive therapy |
|---|---|
| Sponsor | Center of Personalized Medicine, Pirogova |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Nutritional Ketosis Marfan (NA)
- BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT (NA)
- REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study (NA)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity (PHASE3)
- Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study (NA)
- The Effect of Pharmacist-Initiated Home Blood Pressure Monitoring on Blood Pressure Control in Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- antihypertensive therapy CI brief — competitive landscape report
- antihypertensive therapy updates RSS · CI watch RSS
- Center of Personalized Medicine, Pirogova portfolio CI
Frequently asked questions about antihypertensive therapy
What is antihypertensive therapy?
Who makes antihypertensive therapy?
What development phase is antihypertensive therapy in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing